BMO Capital Reiterates Outperform on Acrivon Therapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Etzer Darout has reiterated an Outperform rating on Acrivon Therapeutics (NASDAQ:ACRV) and maintained a $25 price target.
May 15, 2024 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has reiterated an Outperform rating on Acrivon Therapeutics and maintained a $25 price target, indicating continued confidence in the company's performance.
The reiteration of an Outperform rating and the maintenance of a $25 price target by BMO Capital suggests strong confidence in Acrivon Therapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100